HPV16 L1抗体

HPV16 L1抗体产品信息免疫原 : Recombinant HPV16 L1 virus like particle

Antibody Type : Mouse Monoclonal Antibody ( Mouse mAb Service Platform )
克隆号 : 01
抗体宿主 : Mouse IgG1
缓冲液 : 0.2 μm filtered solution in PBS, 5% trehalose may be added in some batches. Please read the hardcopy of COA or contact our customer service to confirm the formulation.
制备方法 : This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant HPV16 L1 virus like particle. The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
HPV16 L1抗体 Background
Papillomaviruses are highly species-specific and can cause squamous epithelial and fibroepithelial tumors in their hosts. Human papillomaviruses (HPVs) are associated with benign and malignant hyperproliferation of cells, with a wide variety of clinical manifestations ranging from condyloma acuminata to cervical carcinoma. HPV infection is the most common sexually transmitted disease. More than 40 HPV types so far identified are known to infect the genital tract. Genital HPVs are divided into `low risk' HPVs such as HPV 6 and 11 and 'high risk' HPV types such as 16, 18, 31, 33, 35, 39, 45 and 52, 58 which are responsible for more than 95% of HPV-induced cervical cancer. Vaccination against these high risk types seems to be the most feasible prevention for cervical cancer. Indeed, clinical trials have shown prophylactic HPV vaccines to be effective against HPV infection, cervical intraepithelial neoplasia (CIN), and genital warts, but protection is type-specific and the currently developed vaccines target only a few types. These vaccines are based on papillomavirus-like particles (VLPs) composed of the major capsid protein, L1. The L1 protein self assembles into VLPs when expressed at high levels in eukaryotic or insect cells. VLPs are composed of 360 copies of L1 protein organized into 72 pentamers, so called capsomeres, to form particles which are immunologically indistinguishable from native virions. Experimentally induced VLP antisera have been shown to be mostly typespecific with respect to neutralization. Minor cross-neutralization has been observed only between closely related HPV types, e.g. HPV6 and 11, HPV18 and 45, or HPV16 and 31. Structure analysis has revealed the presence of several hyper variable loops on the outer surface of the capsid. With a few exceptions, all HPV-neutralizing monoclonal antibodies analyzed so far are type-specific and recognize conformational epitopes within surface-exposed hyper variable loops of the major capsid protein L1.
HPV16 L1抗体相关产品如下：xy-4292R BPI杀菌/通透性增强蛋白抗体
xy-4563R Bcl-2Bcl-2抗体
xy-8202R BRN4脑转录因子4蛋白抗体
xy-5042R Bile salt-activated lipase胆盐激活脂肪酶抗体
xy-5041R BDH13-羟丁酸脱氢酶抗体
xy-5040R BAAT长链脂肪酸酰基辅酶A水解酶抗体
xy-8444R Phospho-BRCA1(Ser988)磷酸化乳腺癌易感基因1抗体
xy-5215R phospho-BACE1 (Ser498)磷酸化β分泌酶抗体
xy-5216R Phospho-Bad (Ser118)磷酸化相关死亡促进因子抗体
xy-5217R Phospho-Bad (Ser134)磷酸化相关死亡促进因子抗体
xy-5220R Phospho-Bcl-2(Thr129)磷酸化Bcl-2抗体
xy-5221R Phospho-BRCA1 (Ser1189)磷酸化乳腺癌易感基因1抗体
xy-5222R Phospho-BRCA1 (Ser1423)磷酸化乳腺癌易感基因1抗体
xy-5223R Phospho-BMX (Tyr556)磷酸化非受体性蛋白酪氨酸激酶ETK抗体
xy-5224R phospho-B-Raf (Thr401)磷酸化B-Raf抗体
xy-4092R BACH1乳腺癌易感基因相互作用蛋白1抗体
xy-5226R phospho-BACH1 (Ser990)磷酸化乳腺癌易感基因相互作用蛋白1抗体
xy-5219R phospho-BAD (Ser99)磷酸化相关死亡促进因子抗体
xy-5230R phospho-Bid (Ser65)磷酸化BH3结构域凋亡诱导蛋白抗体
xy-5231R phospho-Bid (Ser61)磷酸化BH3结构域凋亡诱导蛋白抗体
xy-5232R phospho-B-Raf (Ser446)磷酸化B-Raf抗体
xy-5233R phospho-B-Raf (Thr597)磷酸化B-Raf抗体
xy-5234R phospho-Bcl-xL (Thr115)磷酸化Bcl-xL蛋白抗体
xy-7698R BTG3高表达神经上皮蛋白BTG3抗体
xy-7699R BTG4B细胞迁移基因4抗体
xy-7071R BCL2 interacting proteinBCL2相互作用蛋白质抗体
xy-10077R Brain2大脑蛋白2抗体
xy-7463R BATFB细胞转录激活因子抗体
xy-13606R BCL6BBCL6B抗体
xy-6648R BAP31BAP31蛋白抗体
xy-6589R BCAT2支链氨基酸转氨酶2抗体
xy-6590R Bcl2A1BCL2相关蛋白A1抗体
xy-6591R Bcl3B细胞淋巴瘤蛋白3抗体
xy-5960R B MyB转录因子MYB相关蛋白B抗体
xy-2165R beta Defensin 1防御素β1/Defensin β1抗体
xy-2472R BAFFRB细胞活化因子受体抗体
xy-2431R BAFFTNF家族B细胞激活因子抗体